Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | ZDHHC7 | Q9NXF8 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9834673 | 0.92 | CES2 (0.50) | ZDHHC7ALDH1A1CES2CES1MEN1 | |
| SCHEMBL14800513 | 0.92 | CES2 (0.50) | ZDHHC7ALDH1A1CES2CES1MEN1 | |
| SCHEMBL882565 | 0.84 | ALDH1A1 (0.41) | CA1ALDH1A1TP53CES2CES1 | |
| SCHEMBL1398170 | 0.79 | CA1 (0.38) | CA1CA2ZDHHC7ALDH1A1KMT2A | |
| SCHEMBL7209898 | 0.78 | CA1 (0.47) | CA1CA2ZDHHC7CES2CES1 | |
| SCHEMBL11372771 | 0.77 | CES2 (0.50) | ALDH1A1CES2CES1FAAH | |
| SCHEMBL4115354 | 0.77 | ALDH1A1 (0.46) | CA1ALDH1A1TP53CES2CES1 | |
| SCHEMBL873970 | 0.77 | ALDH1A1 (0.46) | CA2ALDH1A1TP53CES2CES1 | |
| SCHEMBL6221021 | 0.76 | ZDHHC7 (0.52) | CA1CA2ZDHHC7ALDH1A1TP53 | |
| SCHEMBL11657995 | 0.76 | CA1 (0.46) | CA1CA2ZDHHC7ALDH1A1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1794159-B1 | 7-AZAINDOLES AND THEIR USE AS PPAR AGONISTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2012-08-01 | — | — | EP | disclosed |
| EP-1735303-B1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMA INC (US) | 2011-04-27 | — | — | EP | disclosed |
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-7709509-B2 | Oxadiazolones and derivatives thereof as peroxisome proliferator-activated receptor (PPAR) delta agonists | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| CN-100582104-C | Oxadiazolone derivatives as PPAR delta agonists | SANOFI AVENTIS DEUTSCHLAND | 2010-01-20 | — | — | CN | disclosed |
| US-7576109-B2 | 1,3,4-oxadiazol-2-ones as PPAR delta modulators and their use thereof | AVENTIS PHARMACEUTICALS INC. (US) | 2009-08-18 | — | — | US | disclosed |
| EP-2083006-A1 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| EP-2083006-A1 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | Sanofi-Aventis Deutschland GmbH (DE) | 2009-07-29 | — | — | EP | disclosed |
| CN-100516065-C | 1,3, 4-oxadiazol-2-ones as PPAR-Δ modulators | AVENTIS PHARMA INC (US) | 2009-07-22 | — | — | CN | disclosed |
| CN-1938300-A | Oxadiazolone derivatives as PPAR delta agonists | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-03-28 | — | — | CN | disclosed |
| CN-1938305-A | 1,3,4-oxadiazol-2-ones as ppar delta modulators and their use thereof | SANOFI AVENTIS DEUTSCHLAND (US) | 2007-03-28 | — | — | CN | disclosed |
| US-20070060626-A1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | AVENTIS PHARMACEUTICALS INC. (US) | 2007-03-15 | — | — | US | disclosed |
| EP-1586573-B1 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | SANOFI AVENTIS DEUTSCHLAND (DE) | 2007-02-07 | — | — | EP | disclosed |
| EP-1740583-A1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-01-10 | — | — | EP | disclosed |
| EP-1735303-A2 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | Aventis Pharmaceuticals, Inc. (US) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006029699-A1 | 7-AZAINDOLES AND THEIR USE AS PPAR AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-03-23 | — | — | WO | disclosed |
| WO-2005097786-A1 | OXADIAZOLONE DERIVATIVES AS PPAR DELTA AGONISTS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2005-10-20 | — | — | WO | disclosed |
| WO-2005097762-A2 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS | AVENTIS PHARMACEUTICALS INC. (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1586573-A1 | Oxadiazolones, processes for their preparation and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2005-10-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060626-A1 | 1,3,4-OXADIAZOL-2-ONES AS PPAR DELTA MODULATORS AND THEIR USE THEREOF | PPARD, PPARA, PPARG | CA1 4682/4885CA2 3884/4885ZDHHC7 304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.